Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond

Executive Summary

Roche’s proficiency at antibody engineering allows it to construct the next-generation molecules needed to translate scientific insights into therapeutic candidates.


Related Content

Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes
Roche's Guide To Success In Oncology
For Roche Immuno-Oncology, It’s Steady As She Goes
INTERVIEW: Roche's Dan Chen Talks Immuno-Oncology Combinations
Roche's Oncology Strategy: The Long Game Comes Into Focus


Related Companies

Related Deals